Bexagliflozin (also known as EGT1442) is a potent and selective SGLT2 inhibitor that effectively reduces blood glucose and HbA(1c) levels in db/db mice while increasing the survival time of stroke-prone rats. The IC(50) values of EGT1442 for human SGLT1 and SGLT2 are 5.6 μM and 2 nM, respectively. In studies involving normal rats and dogs, EGT1442 induces saturated urinary glucose excretion with ED(50) values of 0.38 mg/kg and 0.09 mg/kg, respectively. Additionally, EGT1442 exhibits favorable properties in both in vivo and in vitro studies, indicating its potential positive impact on the management of type 2 diabetes.